[64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma

• Published in: Oncotarget 2016-08, Vol.7 (35), p.56471-56479
• Main Authors: Minn, Il, Koo, Soo Min, Lee, Hye Soo, Brummet, Mary, Rowe, Steven P, Gorin, Michael A, Sysa-Shah, Polina, Lewis, William D, Ahn, Hye-Hyun, Wang, Yuchuan, Banerjee, Sangeeta Ray, Mease, Ronnie C, Nimmagadda, Sridhar, Allaf, Mohamad E, Pomper, Martin G, Yang, Xing
• Format: Article
• Language: English
• Subjects: Animals; Antigens, Neoplasm - chemistry; Carbonic Anhydrase IX - chemistry; Carcinoma, Renal Cell - diagnostic imaging; Carcinoma, Renal Cell - pathology; Cell Line, Tumor; Copper Radioisotopes - chemistry; Female; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms - diagnostic imaging; Kidney Neoplasms - pathology; Ligands; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Positron-Emission Tomography; Protein Binding; Radiopharmaceuticals - chemistry; Research Paper; Tissue Distribution
• ISSN: 1949-2553
• DOI: 10.18632/oncotarget.10602

Carbonic anhydrase IX (CAIX) is a cell surface enzyme that is over-expressed in approximately 95% of cases of clear cell renal cell carcinoma (ccRCC), the most common renal cancer. We synthesized and performed in vitro and in vivo evaluation of a dual-motif ligand, [64Cu]XYIMSR-06, for imaging CAIX expression on ccRCC tumors using positron emission tomography (PET). [64Cu]XYIMSR-06 was generated in yields of 51.0 ± 4.5% (n=5) and specific activities of 4.1 - 8.9 GBq/μmol (110-240 Ci/mmol). Tumor was visualized on PET images by 1 h post-injection with high tumor-to-background levels (>100 tumor-to-blood and -muscle) achieved within 24 h. Biodistribution studies demonstrated a maximum tumor uptake of 19.3% injected dose per gram of radioactivity at 4 h. Tumor-to-blood, -muscle and -kidney ratios were 129.6 ± 18.8, 84.3 ± 21.0 and 2.1 ± 0.3, respectively, at 8 h post-injection. At 24 h a tumor-to-kidney ratio of 7.1 ± 2.5 was achieved. These results indicate pharmacokinetics superior to those of previously reported imaging agents binding to CAIX. [64Cu]XYIMSR-06 is a new low-molecular-weight PET ligand targeting CAIX, which can image localized and metastatic ccRCC.